Journal of Fluorescence

, Volume 21, Issue 3, pp 1001–1007 | Cite as

Spectrofluorimetric Methods for the Determination of Gemifloxacin in Tablets and Spiked Plasma Samples

Flourescence News Article

Abstract

Two new, sensitive and selective spectrofluorimetric methods have been developed for the determination of gemifloxacin (GFX) in tablets and spiked plasma samples. Gemifloxacin, as a primary amine compound, reacts with 7-chloro-4-nitrobenzofurazon (NBD-Cl) (for method A) and fluorescamine (for method B) which are a highly sensitive fluorogenic reagents used in many investigations. For method A, the reaction product was measured spectrofluorimetrically at 516 nm with excitation at 451 nm. The reaction proceeded quantitatively at pH 8.5, 80 °C in 7 min. For method B, the method was based on the reaction between GFX and fluorescamine in borate buffer solution of pH 8.5 to give highly fluorescent derivatives that were measured at 481 nm using an excitation wavelength of 351 nm. The fluorescence intensity was directly proportional to the concentration over the range 40–200 ng mL−1 and 100–1,200 ng mL−1 for method A and B, respectively. Successful applications of the developed methods, for the drug determination in pharmaceutical preparations and spiked plasma samples, were performed.

Keywords

Gemifloxacin 7-Chloro-4-nitrobenzofurazon Fluorescamine Tablets Spiked plasma 

References

  1. 1.
    Hohl AF, Frei R, Punter V, Graevenitz A, Knapp C, Washington J, Johnson D, Jones RN (1998) International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin Microbiol Infect 4:280–284PubMedGoogle Scholar
  2. 2.
    World Medical Association (1996) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsGoogle Scholar
  3. 3.
    Krishna MV, Sankar DG (2008) Utility of δ and π acceptors for the spectrophotometric determination of gemifloxacin mesylate in pharmaceutical formulations. E-J Chem 5(3):493–498Google Scholar
  4. 4.
    Krishna MV, Sankar DG (2008) Spectrophotometric determination of gemifloxacin mesylate in pharmaceutical formulations through ion-pair complex formation. E-J Chem 5(3):515–520Google Scholar
  5. 5.
    Elbashir AA, Saad B, Ali ASM, Al-Azzam KMM, Aboul-Enein HY (2008) Validated stability indicating assay of gemifloxacin and lomefloxacin in tablet formulations by capillary electrophoresis. J Liq Chromatogr Related Technol 31:1465–1477CrossRefGoogle Scholar
  6. 6.
    Doyle E, Fowles SE, McDonnell DF, White SA (2000) Rapid determination of gemifloxacin in human plasma by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B 746:191–198CrossRefGoogle Scholar
  7. 7.
    Lee W, Yong Hong C (2000) Direct liquid chromatographic enantiomer seperation for new fluoroquinolones including gemifloxacin. J Chromatogr A 879(2):113–118PubMedCrossRefGoogle Scholar
  8. 8.
    Cho SI, Shim J, Kim MS, Kim YK (2004) On-line sample cleanup and chiral separation of gemifloxacin in a urinary solution using chiral crown ether as a chiral selector in microchip electrophoresis. J Chromatogr A 1055:241–245PubMedCrossRefGoogle Scholar
  9. 9.
    Ghosh PB, Whitehouse M (1968) 7-Chloro-4-nitrobenzofurazan: a new fluorogenic reagent for amino acids and other amines. Biochem J 108:155–156PubMedGoogle Scholar
  10. 10.
    Undefriend S, Stein S, Bohlem P, Dairman W, Leimgruber W, Weigele M (1972) Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science (Washington, DC) 178:871–872CrossRefGoogle Scholar
  11. 11.
    Taha EA, Salama NN, Fattah L (2006) Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1, 3-diazole (NBD-Cl). Chem Pharm Bull 54(5):653–658PubMedCrossRefGoogle Scholar
  12. 12.
    Darwish IA, Amer SM, Abdine HH, Al-Rayes LI (2009) Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole. J Fluoresc 19(3):463–471PubMedCrossRefGoogle Scholar
  13. 13.
    Hassan EM, Belal F, Al-Deeb OA, Khalil NY (2001) Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole. J AOAC Int 84(4):1017–1024PubMedGoogle Scholar
  14. 14.
    El-Emam AA, Hansen SH, Moustafa MA, El-Ashry SM, El-Sherbiny DT (2004) Determination of lisinopril in dosage forms and spiked human plasma through derivatization with 7-chloro-4-nitrobenzo-2-oxa-1, 3-diazole (NBD-Cl) followed by spectrophotometry or HPLC with fluorimetric detection. J Pharm Biomed Anal 34(1):35–44PubMedCrossRefGoogle Scholar
  15. 15.
    Onal A, Kepekci SE, Oztunc A (2005) Spectrophotometric methods for the determination of the antidepressant drug paroxetine hydrochloride in tablets. J AOAC Int 88(2):490–495PubMedGoogle Scholar
  16. 16.
    Onal A, Sagirli O (2009) Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation. Spectrochim Acta A Mol Biomol Spectrosc 72(1):68–71, Epub 2008 Aug 28PubMedCrossRefGoogle Scholar
  17. 17.
    El-Enany N (2007) Spectrofluorometric determination of fluvoxamine in dosage forms, spiked plasma, and real human plasma by derivatization with fluorescamine. J AOAC Int 90(2):376–383PubMedGoogle Scholar
  18. 18.
    Suliman FE, Al-Lawati ZH, Al-Kindy SM (2008) A spectrofluorimetric sequential injection method for the determination of penicillamine using fluorescamine in the presence of beta-cyclodextrins. J Fluoresc 18(6):1131–1138, Epub 2008 May 22PubMedCrossRefGoogle Scholar
  19. 19.
    Adamou R, Coly A, Douabalé SE, Saleck ML, Gaye-Seye MD, Tine A (2005) J Fluoresc 15(5):679–688PubMedCrossRefGoogle Scholar
  20. 20.
    Aydogmus Z (2009) Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine. J Fluoresc 19(4):673–679, Epub 2009 Jan 28PubMedCrossRefGoogle Scholar
  21. 21.
    Belal F, Abdine H, Al-Majed A, Khalil NY (2002) Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine. J Pharm Biomed Anal 27:253–260PubMedCrossRefGoogle Scholar
  22. 22.
    Segura Carretero A, Cruces-Blanco C, Fernández Peinado S, El Bergmi R, Fernández Gutiérrez A (1999) Fluorimetric determination of procaine in pharmaceutical preparations based on its reaction with fluorescamine. J Pharm Biomed Anal 21:969–974PubMedCrossRefGoogle Scholar
  23. 23.
    Lakowicz JR (1999) Principles of fluorescence spectroscopy. Kluwer Academic/Plenum, New YorkGoogle Scholar
  24. 24.
    Weber G, Teale FWJ (1957) Fluorescence excitation spectrum of organic compounds in solution-Part 1: systems with quantum yield independent of the exciting wavelenght. Trans Faraday Soc 53:640–648CrossRefGoogle Scholar
  25. 25.
    Eastman JW (1967) Quantitative spectrofluorimetry—the fluorescence quantum yield of quinine sulfate. Photochem Photobiol 6:55–72CrossRefGoogle Scholar
  26. 26.
    Rote AR, Pingle SP (2009) Reverse phase-HPLC and HPTLC methods for determination of gemifloxacin mesylate in human plasma. J Chromatogr, B 877(29):3719–3723CrossRefGoogle Scholar
  27. 27.
    Pesez M, Batros J (1974) Colorimetric and fluorimetric analysis of organic compounds and drugs. Marcel Dekker, New York, p 170Google Scholar
  28. 28.
    Imai K, Toyo’oka T, Miyano H (1984) Fluorigenic reagents for primary and secondary amines and thiols in high-performance liquid chromatography: a review. Analyst 109:1365–1373CrossRefGoogle Scholar
  29. 29.
    Imai K, Uzu S, Toyoóka T (1989) Fluorogenic reagents having benzofurazan structure in liquid chromatography. J Pharm Biomed Anal 7:1395–1403PubMedCrossRefGoogle Scholar
  30. 30.
    Job P (1928) Formation and stability of inorganic complexes in solution. Anal Chem 9:113–203Google Scholar
  31. 31.
    Allen A, Bygate E, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS, Kim IC (2000) Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob Agents Chemother 44(6):1604–1608PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Faculty of Pharmacy, Department of Analytical ChemistryIstanbul UniversityIstanbulTurkey
  2. 2.Faculty of Pharmacy, Department of Analytical ChemistryBezmialem Vakif UniversityIstanbulTurkey

Personalised recommendations